Rosuvastatin Tablet, Film Coated
Product Images NDC 68071-3847

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rosuvastatin (NDC 68071-3847). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 3847 2)

Pdp (68071 3847 2)
This is information related to a medication package containing Rosuvastatin 20mg tablets manufactured by uCare Pharmaceuticals, Inc. The package includes details such as NDC numbers, lot numbers, expiration date, and tablet specifications. It also provides a warning to keep the medication out of reach of children and store it at a controlled temperature between 68-77°F. It is important to consult a doctor for medical advice and report any side effects to the FDA.*
FDA Label Image

Figure-01 (Figure 1)

Figure-01 (Figure 1)
This appears to be statistical data related to a study or clinical trial comparing the effects of a treatment (RSV) versus a control (Placebo) on a certain outcome. The data includes information such as the number at risk over a specific duration of time for both groups. The text mentions confidence interval, statistical significance, and the number of subjects at each time point. The study may involve evaluating the impact or effectiveness of the RSV treatment compared to a placebo.*
FDA Label Image

Figure-02 (Figure 2)

Figure-02 (Figure 2)
This text presents a statistical comparison between the effects of Rosuvastatin (20 mg) and Placebo (20 mg) on various cardiovascular events in a total of 8901 patients. The study includes data on primary endpoints (MCE), cardiovascular death, non-fatal stroke, non-fatal MI, hospitalized unstable angina, and arterial revascularization. The hazard ratio (HR) along with confidence intervals and p-values are provided for each event, showing significant benefits of Rosuvastatin in reducing cardiovascular risk compared to Placebo. The results suggest Rosuvastatin may be effective in lowering the risk of cardiovascular events such as stroke, heart attack, and arterial revascularization.*
FDA Label Image

Figure-02 (Figure 3)

Figure-02 (Figure 3)
FDA Label Image

Structural Formula (Rosuvastatin Str)

Structural Formula (Rosuvastatin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.